The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering

被引：5
|
作者：
Farukhi, Zareen [1 ]
Mora, Samia [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Div Prevent Med, Ctr Lipid Metabol, 75 Francis St, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
来源：
CIRCULATION | 2018年 / 137卷 / 01期
关键词：
Editorials; cholesterol; lipids; lipoproteins; LDL; triglycerides;
D O I：
10.1161/CIRCULATIONAHA.117.031857
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：20 / 23
页数：4
相关论文
共 50 条
  • [1] Alirocumab for low-density lipoprotein cholesterol lowering
    Roth, Eli M.
    [J]. FUTURE CARDIOLOGY, 2019, 15 (01) : 17 - 29
  • [2] Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy
    Sathiyakumar, Vasanth
    Park, Jihwan
    Golozar, Asieh
    Lazo, Mariana
    Quispe, Renato
    Guallar, Eliseo
    Blumenthal, Roger S.
    Jones, Steven R.
    Martin, Seth S.
    [J]. CIRCULATION, 2018, 137 (01) : 10 - +
  • [3] Evaluation of Malondialdehyde Low-Density Lipoprotein Stratified by Low-Density Lipoprotein Cholesterol
    Moriyama, Kengo
    Takahashi, Eiko
    [J]. CLINICAL LABORATORY, 2017, 63 (7-8) : 1179 - 1186
  • [4] Pro and con: Low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management
    Pedersen, TR
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (5A): : 8B - 12B
  • [5] Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
    Katsiki, Niki
    Vrablik, Michal
    Banach, Maciej
    Gouni-Berthold, Ioanna
    [J]. PHARMACEUTICALS, 2023, 16 (04)
  • [6] Nonfasting low-density lipoprotein testing: Utility for cholesterol screening in pediatric primary care
    de Ferranti, Sarah
    Shapiro, David
    Markowitz, Robert
    Neufeld, Ellis
    Rifai, Nader
    Bernstein, Henry
    [J]. CLINICAL PEDIATRICS, 2007, 46 (05) : 441 - 445
  • [7] Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment
    Lahoz, C
    Peña, R
    Mostaza, JM
    Laguna, F
    García-Iglesias, MF
    Taboada, M
    Pintó, X
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (06): : 741 - 747
  • [8] The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?
    Khera, Amit V.
    Natarajan, Pradeep
    Kathiresan, Sekar
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2016, 23 (10) : 1062 - 1064
  • [9] Future approaches to reducing low-density lipoprotein cholesterol
    Wierzbicki, Anthony S.
    [J]. FUTURE LIPIDOLOGY, 2006, 1 (04): : 463 - 476
  • [10] Fenofibrate lowers small low-density lipoprotein with no change in total low-density lipoprotein cholesterol
    Superko, HR
    Madan, S
    Tonnemacher, D
    Chronos, N
    Garrett, B
    Sheehan, D
    Raul, E
    Frohwein, S
    McGrath, K
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 316A - 316A
12345